| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1029995991 |
| P356 | DOI | 10.1007/S12325-016-0324-7 |
| P3181 | OpenCitations bibliographic resource ID | 2512591 |
| P932 | PMC publication ID | 4882351 |
| P698 | PubMed publication ID | 27039186 |
| P50 | author | Riad Salem | Q45736667 |
| Ahmed Gabr | Q51535121 | ||
| Joseph R. Kallini | Q55436851 | ||
| P2093 | author name string | Robert J Lewandowski | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols | Q26783881 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization | Q28111719 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients | Q30892049 | ||
| Portal vein embolization before right hepatectomy: prospective clinical trial | Q33964114 | ||
| Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 | ||
| Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post-Radioembolization (90)Y PET. | Q34330202 | ||
| Quantitative and qualitative assessment of Yttrium-90 PET/CT imaging. | Q34450157 | ||
| Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver | Q34563356 | ||
| Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis | Q34621197 | ||
| Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. | Q34695917 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 | ||
| Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis | Q35838619 | ||
| Angiographic considerations in patients undergoing liver-directed therapy | Q36185940 | ||
| Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial | Q36383875 | ||
| Portal vein embolization before liver resection: a systematic review | Q36546055 | ||
| Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 | ||
| PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response | Q36874720 | ||
| Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept | Q36920698 | ||
| Induction of tumor growth after preoperative portal vein embolization: is it a real problem? | Q37339788 | ||
| Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. | Q37376714 | ||
| Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes | Q37669068 | ||
| 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness | Q38162894 | ||
| Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma | Q38214883 | ||
| Transarterial chemoembolization and radioembolization. | Q38264958 | ||
| Hepatic imaging following intra-arterial embolotherapy | Q38716483 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. | Q39310997 | ||
| Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry | Q39949557 | ||
| Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases | Q40011784 | ||
| Outpatient single-session yttrium-90 glass microsphere radioembolization. | Q40157297 | ||
| Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity | Q40192043 | ||
| Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis | Q40444455 | ||
| Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients | Q40893720 | ||
| Radioembolization Versus Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study | Q41005759 | ||
| Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation | Q42601023 | ||
| Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study | Q43738534 | ||
| Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. | Q44153080 | ||
| Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. | Q46182773 | ||
| Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. | Q47300243 | ||
| Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma | Q48058236 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective. | Q50972179 | ||
| Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. | Q51021204 | ||
| Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. | Q51593250 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. | Q53255843 | ||
| Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. | Q53391789 | ||
| Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. | Q53525194 | ||
| Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. | Q54694907 | ||
| Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization | Q56603208 | ||
| Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Q56970979 | ||
| Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 | ||
| Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization | Q63198740 | ||
| Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization | Q63198749 | ||
| Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres | Q73093019 | ||
| Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres | Q74256633 | ||
| Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization | Q82436223 | ||
| A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization | Q84121312 | ||
| Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma | Q85064441 | ||
| Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? | Q86389913 | ||
| Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy | Q87585663 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | yttrium | Q941 |
| embolization | Q1144114 | ||
| hepatocellular carcinoma | Q1148337 | ||
| liver neoplasm | Q18558073 | ||
| therapeutic chemoembolization | Q68572802 | ||
| P304 | page(s) | 699-714 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma | |
| P478 | volume | 33 |
| Q40091767 | Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. |
| Q42362049 | Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trial |
| Q92344068 | Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC) |
| Q55283883 | Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know. |
| Q50026313 | Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma |
| Q38792625 | Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation |
| Q95643083 | Lung Metastasis Postradioembolization of Hepatocellular Carcinoma With Tumor in Vein |
| Q92484964 | Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma |
| Q92573136 | Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma |
| Q90746918 | Position 1: Transarterial Chemoembolization Should Be the Primary Locoregional Therapy for Unrespectable Hepatocelluar Carcinoma |
| Q38616345 | Proton beam therapy for hepatocellular carcinoma |
| Q33872976 | Radioembolization for the treatment of hepatocellular carcinoma |
| Q47916271 | Radionuclides in oncology clinical practice - review of the literature |
| Q90430543 | Skin ischemia and ulceration as a complication of inferior phrenic artery embolization for hepatocellular carcinoma |
| Q50209684 | Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases |
| Q61453275 | Transarterial Radioembolization (TARE) Agents beyond Y-Microspheres |
| Q38652404 | Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres |
| Q38728540 | Update on Embolization Therapies for Hepatocellular Carcinoma |
| Q54988323 | Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? |
Search more.